Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elidel, Protopic Get Boxed Warnings On Cancer, But Not At Top Of Labeling

Executive Summary

Boxed warnings about potential cancer risks will appear in the warning sections for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus)

You may also be interested in...



Exelon Dementia Indication May Revive Flagging Sales, Novartis Says

Sales of Novartis' Alzheimer's disease therapy Exelon (rivastigmine tartrate) have taken a hit in the U.S. due to increased competition, the company said

Novartis To Maintain Sales Force In Face Of Potential Competitor Cutbacks

Novartis' decision to maintain its current sales force level could reflect the company's confidence in the continued growth of its pharmaceutical business

Elidel, Protopic “Black Box” Could Be Test Of FDA’s Labeling Authority

FDA's proposal to add a "black box" to labeling of the eczema treatments Elidel and Protopic could be a high-profile test of the agency's ability to change product labeling following recent congressional discussion of the agency's authority

Related Content

UsernamePublicRestriction

Register

PS046779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel